title: Paclitaxel, cisplatin, and vinorelbine combination chemotherapy in metastatic non-small-cell lung cancer.
abstract: Vinorelbine-cisplatin combination chemotherapy is a standard approach for the treatment of advanced non-small-cell lung cancer (NSCLC). The addition of paclitaxel as a third therapeutic agent seems promising. The aim of the present study was to evaluate the activity and toxicity of this new regimen. Forty-six nonselected and chemotherapy-naive patients with stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0 to 2 were treated every 4 weeks with paclitaxel (135 mg/m2 given iv in 3 hours) and cisplatin (120 mg/m2 given iv in 6 hours) on day 1 and vinorelbine (30 mg/m2 given iv in 30 minutes) on days 1 and 15. All patients were evaluated for toxicity and response according to the intent-to-treat principle. An objective response was observed in 39% of the patients (95% CI: 25% to 55%). World Health Organization grade III to IV neutropenia, thrombocytopenia, and anemia occurred in 43%, 2%, and 17%, respectively. There was one treatment-related death. Nonhematologic toxicities were mild, mainly grade III nausea and vomiting in 20% of the patients. After a median follow-up period of 54 months, the median progression-free survival was 14.3 weeks and the median overall survival was 31.3 weeks. This three-drug chemotherapy combination is feasible, well tolerated, and shows activity in metastatic NSCLC.
authors.affiliation: Department of Oncology, Clínica Universitaria de Navarra, Pamplona, Spain. jccastan@unav.es
authors.forename: Javier
authors.initials: J
authors.lastname: Cortes
authors.forename: Javier
authors.initials: J
authors.lastname: Rodriguez
authors.forename: Emiliano
authors.initials: E
authors.lastname: Calvo
authors.forename: Alfonso
authors.initials: A
authors.lastname: Gurpide
authors.forename: Jesus
authors.initials: J
authors.lastname: Garcia-Foncillas
authors.forename: Esteban
authors.initials: E
authors.lastname: Salgado
authors.forename: Jose Manuel
authors.initials: JM
authors.lastname: Aramendia
authors.forename: Jose Maria
authors.initials: JM
authors.lastname: Lopez-Picazo
authors.forename: Berta
authors.initials: B
authors.lastname: Hernandez
authors.forename: Rebeca
authors.initials: R
authors.lastname: Hidalgo
authors.forename: Jose Javier
authors.initials: JJ
authors.lastname: Aristu
authors.forename: Antonio
authors.initials: A
authors.lastname: Brugarolas
authors.forename: Salvador
authors.initials: S
authors.lastname: Martin-Algarra
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000556:secondary; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D016019:Survival Analysis; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077235:Vinorelbine
chemical_list: D014747:Vinblastine; D017239:Paclitaxel; D002945:Cisplatin; D000077235:Vinorelbine